Aprea Therapeutics Stock Forum

$Aprea Therapeutics (APRE.US)$
$APRE holding $3 like a champ again! 💪🔥
Just need that volume boost and a push past $3.15 to light the fuse! 🚀
https://chartingdaily.com/advancing-cancer-care-with-dna
Communicated Disclaimer
$PainReform (PRFX.US)$ $AppTech Payments (APCX.US)$ $Micron Technology (MU.US)$ $Nukkleus (NUKK.US)$

$Biodexa Pharmaceuticals (BDRX.US)$ $Kirkland's (KIRK.US)$ $DocuSign (DOCU.US)$ $Aprea Therapeutics (APRE.US)$ $HilleVax (HLVX.US)$ $Asana (ASAN.US)$ $Rubrik (RBRK.US)$ $Cardio Diagnostics (CDIO.US)$ $Gaxos.ai (GXAI.US)$ $Universe Pharmaceuticals (UPC.US)$ $Northann (NCL.US)$ $Primega Group (PGHL.US)$ $The Lion Electric (LEV.US)$ $Zhibao Technology (ZBAO.US)$
📊⚡️📊

$Aprea Therapeutics (APRE.US)$
Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics
Aprea Therapeutics (APRE) presented preliminary safety results for its WEE1 inhibitor APR-1051 at the EORTC-NCI-AACR Symposium. The Phase 1 ACESOT-1051 trial is evaluating APR-1051 as monotherapy in advanced solid tumors. Data from two of three enrolled patients show the drug is safe and well-tolerated ...

$Aprea Therapeutics (APRE.US)$
Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051
Aprea Therapeutics has announced the dosing of the first patient in the ACESOT-1051 Phase 1 trial for their oral WEE1 inhibitor, APR-1051. This study is evaluating APR-1051 as a monotherapy for patients with advanced solid tumors who have unmet medical needs. APR-1051, developed by Aprea, targets the WEE1 kinase, an enzyme involved in the DNA dam...

$Aprea Therapeutics (APRE.US)$
Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial
Aprea Therapeutics announced that the Safety Review Committee (SRC) has approved dosing patients with ATRN-119 at 800 mg once daily in the ongoing ABOYA-119 clinical trial. ATRN-119, the first macrocyclic ATR inhibitor in clinic trials, has demonstrated a favorable safety profile through five dosage le...

$Aprea Therapeutics (APRE.US)$
NEWS
Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024
Aprea Therapeutics, Inc. announces positive pre-clinical findings for APR-1051, a WEE1 kinase inhibitor, indicating potential as a treatment for Cyclin E-overexpressing cancers. The company also received IND clearance for APR-1051 and presented details on the planned Phase 1 trial. ATRN-119, a n...

$Aprea Therapeutics (APRE.US)$ Karolinska Development's Portfolio Company Aprea Therapeutics Receives FDA IND Approval and Secures Funding of USD 34 Million
GlobeNewswire· 4 mins ago

$Aprea Therapeutics (APRE.US)$ buy now